AUS
NZ
UK
CA
USA
IND
_05_28_2024_07_35_45_631343.jpg)
In a day where the S&P/ASX 200 Index (ASX:XJO) is tracking for another decline, three ASX-listed shares are defying the market trend. On Thursday the benchmark index closed down 0.49% to 7,628.20 points. However, Catapult Group International Ltd, Clarity Pharmaceuticals Ltd, and Pro Medicus Limited are among the stocks pushing higher. Here’s a look at why these shares are rising.
Catapult Group International Ltd (ASX: CAT)
Catapult Group's share price has surged 9.68% to AU$1.70 apiece following the release of its strong full-year results for FY 2024. The sports technology solutions provider reported a 20% increase in revenue, reaching a record US$100 million. This growth was primarily driven by a 24% increase in SaaS revenue, which hit US$82 million. Notably, Catapult also delivered on its guidance to generate positive free cash flow (FCF) in FY 2024, achieving FCF of US$4.6 million—a significant improvement of US$26.2 million year-on-year. Investors are optimistic about the company’s performance and future prospects.
Clarity Pharmaceuticals Ltd (ASX: CU6)
Clarity Pharmaceuticals' share price has climbed 1.52% to AU$4.67 apiece after the clinical-stage radiopharmaceutical company announced a new supply agreement with SpectronRx. The agreement focuses on the production of Cu-64, a radiopharmaceutical with an ideal 12.7-hour half-life. This advancement is set to alleviate the supply constraints of current-generation radiodiagnostics, reducing scheduling pressures on imaging centers and enhancing product performance with longer imaging timepoints. The market has responded positively to this development, reflecting confidence in Clarity’s strategic advancements.
Pro Medicus Limited (ASX: PME)
Pro Medicus shares have increased by another 3.61% to AU$120.07 apiece, continuing a positive trend for the health imaging company. This week, Pro Medicus announced five new contracts with a combined minimum value of $45 million. These contracts will be fully cloud-deployed and are expected to be completed within the next six months. In response, Goldman Sachs reiterated its buy rating on Pro Medicus shares, raising the price target to $136.00. Investors are buoyed by the company's robust contract pipeline and strong growth outlook.
Market Context and Outlook
While the broader ASX market faces downward pressure due to various economic factors, including weak commodity prices and high natural gas costs, certain sectors and companies are showing resilience. The performances of Catapult Group, Clarity Pharmaceuticals, and Pro Medicus highlight the strength of innovative and strategically positioned companies in navigating market challenges and seizing growth opportunities.
